<p>马萨诸塞州剑桥，2025 年 12 月 18 日（GLOBE NEWSWIRE）——CAMP4 Therapeutics Corporation（“CAMP4” 或 “公司”）（纳斯达克：CAMP）是一家临床阶段的生物制药公司，正在开发一系列针对 RNA 的治疗药物，旨在上调基因表达，以恢复健康的蛋白质水平，治疗广泛的遗传疾病。今天，公司宣布以每股 6.00 美元的价格定价其 500 万股普通股的承销发行。预计此次发行的公司总收入为 3000 万美元，未扣除承销折扣和佣金及其他发行费用。</p>
<p>此次发行预计将在 2025 年 12 月 19 日左右完成，具体取决于满足惯例的交割条件。所有将在此次发行中出售的证券均由公司提供。</p>
<p>CAMP4 目前预计将使用此次发行的净收益，以及现有的现金、现金等价物和可交易证券，主要支持其产品候选药物的持续开发活动，以及一般企业用途。</p>
<p>此次融资包括来自新投资者和现有投资者的参与，包括一家大型共同基金、Janus Henderson Investors、Coastlands Capital、EcoR1 Capital、Trails Edge Capital Partners 和 Vivo Capital。</p>
<p>Leerink Partners 担任此次发行的唯一承销商。</p>
<p>与这些证券相关的 S-3 表格注册声明（文件编号：333-291432）已向证券交易委员会（“SEC”）提交，并于 2025 年 12 月 1 日生效。此次发行仅通过招股说明书补充和随附的招股说明书进行。与此次发行相关的招股说明书补充和随附的基础招股说明书将提交给 SEC，并可在 SEC 网站 http://www.sec.gov 上获取。可用时，相关的招股说明书补充和随附的招股说明书的副本可从 Leerink Partners LLC 获取，注意：承销部，地址：马萨诸塞州波士顿州立街 53 号，40 层，邮政编码 02109，或拨打电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不合，均属非法。</p>
<p><strong>关于 CAMP4 Therapeutics</strong></p>
<p>CAMP4 正在开发针对广泛遗传疾病的疾病修饰治疗，这些疾病通过增强健康蛋白质可能提供治疗益处。我们的方法通过利用基因控制的基本机制来增强 mRNA。为了增强 mRNA，我们的治疗性 ASO 药物候选者针对调控 RNA（“regRNAs”），这些 RNA 在转录因子上局部作用，是基因表达的主要调节因子。CAMP4 的专有 RAP 平台®能够绘制 regRNAs 并生成旨在针对与基因相关的 regRNAs 的治疗候选者，这些基因与单倍体不足和隐性部分功能丧失疾病相关，这类疾病超过 1200 种，适度增加蛋白质表达可能具有临床意义。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，这些声明涉及风险、不确定性和意外情况，其中许多超出了公司的控制范围，可能导致实际结果、表现或成就与预期结果、表现或成就存在重大差异。除本新闻稿中历史事实的陈述外，所有陈述均为前瞻性声明。在某些情况下，您可以通过 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些词。</p>
<p>这些前瞻性声明受到多种风险、不确定性和假设的影响，包括预期的发行时间、市场条件以及与发行相关的惯常成交条件的满足，市场条件相关的风险和不确定性；公司普通股交易价格的波动；实现监管里程碑的固有风险；公司有限的运营历史，自公司成立以来发生了重大亏损，并预计在可预见的未来将继续发生重大且不断增加的亏损；公司实现目标所需的额外融资的巨大需求；临床开发的不确定性，这一过程漫长且昂贵，结果不确定，以及与完成或未能完成公司当前产品候选者或任何未来产品候选者的开发和商业化相关的额外成本或延误的风险；在临床试验中招募和给药患者的延误或困难；公司产品候选者引起的任何重大不良事件或不良副作用的影响；潜在竞争，包括来自大型和专业制药及生物技术公司的竞争；公司实现当前或未来合作或许可安排的利益的能力，以及成功完成未来合作的能力；公司在美国或其他司法管辖区获得商业化任何产品候选者的监管批准的能力，以及任何此类批准可能比公司所寻求的适应症更为狭窄的风险；公司对高级管理人员及其他临床和科学人员服务的依赖，以及公司留住这些个人或招聘额外管理或临床和科学人员的能力；公司扩大组织的能力，以及管理公司增长和运营扩展的能力；与公司产品候选者的制造相关的风险，这一过程复杂，以及公司第三方制造商在生产中可能遇到的困难的风险；公司获得和维持对公司产品候选者或公司可能开发的任何未来产品候选者的足够知识产权保护的能力；公司依赖第三方进行公司的前临床研究和临床试验；公司遵守根据他人授予公司的许可所承担的义务，以开发和商业化公司的产品候选者的权利；与公司供应商的运营相关的风险；以及在公司截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分和截至 2025 年 9 月 30 日的季度报告中描述的其他风险和不确定性，以及公司向 SEC 提交的其他信息。本新闻稿中的前瞻性声明本质上是不确定的，并不能保证未来事件的发生。由于前瞻性声明本质上受到风险和不确定性的影响，其中一些无法预测或量化，且有些超出公司的控制范围，因此您不应过度依赖这些前瞻性声明。前瞻性声明中反映的事件和情况可能无法实现或发生，实际未来的结果、活动水平、表现以及事件和情况可能与前瞻性声明中预测的有实质性差异。此外，公司在一个不断发展的环境中运营。新的风险和不确定性可能会不时出现，管理层无法预测所有风险和不确定性。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。除非法律要求，否则公司不承诺公开更新或修订此处包含的任何前瞻性声明，无论是由于任何新信息、未来事件、情况变化或其他原因。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者关系：</strong></p>
<p>Sara Michelmore</p>
<p>Milestone Advisors</p>
<p><strong>sara@milestone-advisorsllc.com</strong></p>
<p><strong>媒体：</strong></p>
<p>Jason Braco, Ph.D.</p>
<p>LifeSci Communications</p>
<p>jbraco@lifescicomms.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ETXhNeU0zTXpJNE1UY3hJekl5TmpFM01UUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ETXhNeU0zTXpJNE1UY3hJekl5TmpFM01UUT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzRjMjRlZmQtZTc0Yi00NmY4LTk3NzgtZGUyODhjYTRiZmFkLTEyNzMyNjQtMjAyNS0xMi0xOC1lbg==/tiny/CAMP4-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzRjMjRlZmQtZTc0Yi00NmY4LTk3NzgtZGUyODhjYTRiZmFkLTEyNzMyNjQtMjAyNS0xMi0xOC1lbg==/tiny/CAMP4-Therapeutics.png"/></p>

CAMP

<p>CAMP4 Therapeutics Corporation 宣布以每股 6.00 美元的价格定价其 3000 万美元的承销发行，发行 5,000,000 股普通股。该发行预计将于 2025 年 12 月 19 日完成。所得款项将用于支持开发活动和一般企业用途。Leerink Partners 是唯一的承销商。已向 SEC 提交注册声明。本新闻稿包含面临风险和不确定性的前瞻性声明</p>

<p>CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥，2025 年 12 月 18 日（GLOBE NEWSWIRE）——CAMP4 Therapeutics Corporation（“CAMP4” 或 “公司”）（纳斯达克：CAMP）是一家临床阶段的生物制药公司，正在开发一系列针对 RNA 的治疗药物，旨在上调基因表达，以恢复健康的蛋白质水平，治疗广泛的遗传疾病。今天，公司宣布以每股 6.00 美元的价格定价其 500 万股普通股的承销发行。预计此次发行的公司总收入为 3000 万美元，未扣除承销折扣和佣金及其他发行费用。</p>
</div><p>The offering is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by the Company.</p>
<div class="lb-trans"><p>此次发行预计将在 2025 年 12 月 19 日左右完成，具体取决于满足惯例的交割条件。所有将在此次发行中出售的证券均由公司提供。</p>
</div><p>CAMP4 currently anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, primarily to support continued development activities for its product candidates, as well as general corporate purposes.</p>
<div class="lb-trans"><p>CAMP4 目前预计将使用此次发行的净收益，以及现有的现金、现金等价物和可交易证券，主要支持其产品候选药物的持续开发活动，以及一般企业用途。</p>
</div><p>The financing includes participation from new and existing investors, including a large mutual fund complex, Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, and Vivo Capital.</p>
<div class="lb-trans"><p>此次融资包括来自新投资者和现有投资者的参与，包括一家大型共同基金、Janus Henderson Investors、Coastlands Capital、EcoR1 Capital、Trails Edge Capital Partners 和 Vivo Capital。</p>
</div><p>Leerink Partners is acting as the sole underwriter for the offering.</p>
<div class="lb-trans"><p>Leerink Partners 担任此次发行的唯一承销商。</p>
</div><p>A registration statement on Form S-3 (File No. 333-291432) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on December 1, 2025. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and available on the SEC’s website located at http://www.sec.gov. When available, copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.</p>
<div class="lb-trans"><p>与这些证券相关的 S-3 表格注册声明（文件编号：333-291432）已向证券交易委员会（“SEC”）提交，并于 2025 年 12 月 1 日生效。此次发行仅通过招股说明书补充和随附的招股说明书进行。与此次发行相关的招股说明书补充和随附的基础招股说明书将提交给 SEC，并可在 SEC 网站 http://www.sec.gov 上获取。可用时，相关的招股说明书补充和随附的招股说明书的副本可从 Leerink Partners LLC 获取，注意：承销部，地址：马萨诸塞州波士顿州立街 53 号，40 层，邮政编码 02109，或拨打电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不合，均属非法。</p>
</div><p><strong>About CAMP4 Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 CAMP4 Therapeutics</strong></p>
</div><p>CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (“regRNAs”), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful.</p>
<div class="lb-trans"><p>CAMP4 正在开发针对广泛遗传疾病的疾病修饰治疗，这些疾病通过增强健康蛋白质可能提供治疗益处。我们的方法通过利用基因控制的基本机制来增强 mRNA。为了增强 mRNA，我们的治疗性 ASO 药物候选者针对调控 RNA（“regRNAs”），这些 RNA 在转录因子上局部作用，是基因表达的主要调节因子。CAMP4 的专有 RAP 平台®能够绘制 regRNAs 并生成旨在针对与基因相关的 regRNAs 的治疗候选者，这些基因与单倍体不足和隐性部分功能丧失疾病相关，这类疾病超过 1200 种，适度增加蛋白质表达可能具有临床意义。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，这些声明涉及风险、不确定性和意外情况，其中许多超出了公司的控制范围，可能导致实际结果、表现或成就与预期结果、表现或成就存在重大差异。除本新闻稿中历史事实的陈述外，所有陈述均为前瞻性声明。在某些情况下，您可以通过 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些词。</p>
</div><p>These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions related to the offering, risks and uncertainties related to market conditions; volatility in the trading price of the Company’s common stock; risks inherent in achieving regulatory milestones; the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other information the Company files with the SEC. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<div class="lb-trans"><p>这些前瞻性声明受到多种风险、不确定性和假设的影响，包括预期的发行时间、市场条件以及与发行相关的惯常成交条件的满足，市场条件相关的风险和不确定性；公司普通股交易价格的波动；实现监管里程碑的固有风险；公司有限的运营历史，自公司成立以来发生了重大亏损，并预计在可预见的未来将继续发生重大且不断增加的亏损；公司实现目标所需的额外融资的巨大需求；临床开发的不确定性，这一过程漫长且昂贵，结果不确定，以及与完成或未能完成公司当前产品候选者或任何未来产品候选者的开发和商业化相关的额外成本或延误的风险；在临床试验中招募和给药患者的延误或困难；公司产品候选者引起的任何重大不良事件或不良副作用的影响；潜在竞争，包括来自大型和专业制药及生物技术公司的竞争；公司实现当前或未来合作或许可安排的利益的能力，以及成功完成未来合作的能力；公司在美国或其他司法管辖区获得商业化任何产品候选者的监管批准的能力，以及任何此类批准可能比公司所寻求的适应症更为狭窄的风险；公司对高级管理人员及其他临床和科学人员服务的依赖，以及公司留住这些个人或招聘额外管理或临床和科学人员的能力；公司扩大组织的能力，以及管理公司增长和运营扩展的能力；与公司产品候选者的制造相关的风险，这一过程复杂，以及公司第三方制造商在生产中可能遇到的困难的风险；公司获得和维持对公司产品候选者或公司可能开发的任何未来产品候选者的足够知识产权保护的能力；公司依赖第三方进行公司的前临床研究和临床试验；公司遵守根据他人授予公司的许可所承担的义务，以开发和商业化公司的产品候选者的权利；与公司供应商的运营相关的风险；以及在公司截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分和截至 2025 年 9 月 30 日的季度报告中描述的其他风险和不确定性，以及公司向 SEC 提交的其他信息。本新闻稿中的前瞻性声明本质上是不确定的，并不能保证未来事件的发生。由于前瞻性声明本质上受到风险和不确定性的影响，其中一些无法预测或量化，且有些超出公司的控制范围，因此您不应过度依赖这些前瞻性声明。前瞻性声明中反映的事件和情况可能无法实现或发生，实际未来的结果、活动水平、表现以及事件和情况可能与前瞻性声明中预测的有实质性差异。此外，公司在一个不断发展的环境中运营。新的风险和不确定性可能会不时出现，管理层无法预测所有风险和不确定性。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。除非法律要求，否则公司不承诺公开更新或修订此处包含的任何前瞻性声明，无论是由于任何新信息、未来事件、情况变化或其他原因。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投资者关系：</strong></p>
</div><p>Sara Michelmore</p>
<div class="lb-trans"><p>Sara Michelmore</p>
</div><p>Milestone Advisors</p>
<div class="lb-trans"><p>Milestone Advisors</p>
</div><p><strong>sara@milestone-advisorsllc.com</strong></p>
<div class="lb-trans"><p><strong>sara@milestone-advisorsllc.com</strong></p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Jason Braco, Ph.D.</p>
<div class="lb-trans"><p>Jason Braco, Ph.D.</p>
</div><p>LifeSci Communications</p>
<div class="lb-trans"><p>LifeSci Communications</p>
</div><p>jbraco@lifescicomms.com</p>
<div class="lb-trans"><p>jbraco@lifescicomms.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ETXhNeU0zTXpJNE1UY3hJekl5TmpFM01UUT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDMxMyM3MzI4MTcxIzIyNjE3MTQ="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzRjMjRlZmQtZTc0Yi00NmY4LTk3NzgtZGUyODhjYTRiZmFkLTEyNzMyNjQtMjAyNS0xMi0xOC1lbg==/tiny/CAMP4-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/NzRjMjRlZmQtZTc0Yi00NmY4LTk3NzgtZGUyODhjYTRiZmFkLTEyNzMyNjQtMjAyNS0xMi0xOC1lbg==/tiny/CAMP4-Therapeutics.png"/></p>

CAMP4 宣布以 3000 万美元的价格进行普通股承销发行 | CAMP 股票新闻